Evidence map›Paper›PMID 34308258›Full record

ArticleSN comprehensive clinical medicine2021

Possible Reactivation of SARS-CoV-2 in a Patient with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Case Report.

Vera Dalla Via, Matthias von Rotz, Veronika Bättig, Karoline Leuzinger, Hans H Hirsch, Jakob Passweg, Georg Stüssi, Michael Medinger

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in SN comprehensive clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vera Dalla ViaDivision of Hematology, Department of Medicine, University Hospital Basel and University of Basel, Petersgraben 4, CH-4031 Basel, Switzerland.
Matthias von RotzDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Basel and University of Basel, Basel, Switzerland.
Veronika BättigDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Basel and University of Basel, Basel, Switzerland.
Karoline LeuzingerClinical Virology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland.
Hans H HirschDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Basel and University of Basel, Basel, Switzerland.
Jakob PasswegDivision of Hematology, Department of Medicine, University Hospital Basel and University of Basel, Petersgraben 4, CH-4031 Basel, Switzerland.
Georg StüssiOncological Institute of Italian Switzerland, Bellinzona, Switzerland.
Michael MedingerDivision of Hematology, Department of Medicine, University Hospital Basel and University of Basel, Petersgraben 4, CH-4031 Basel, Switzerland.ORCID 0000-0003-0427-7747

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reactivation or reinfection cases of SARS-CoV-2 are known but there is scarce evidence about reactivation in immunocompromised patients. Here, we report the case of a 61-year-old male undergoing a conditioning regimen with fludarabine, cyclophosphamide, and 2-Gy total body irradiation in preparation of a haplo-identical allogeneic hematopoietic stem cell transplantation (allo-HSCT) for acute myeloid leukemia (AML). He received the first dose of a COVID-19 vaccine 6 weeks prior allo-HSCT and was hospitalized a month prior because of a COVID-19 bilateral pneumonia. On discharge, he showed two negative SARS-CoV-2 nasopharyngeal PCR swabs as well as a high SARS-CoV-2 antibody titer. On admission for allo-HSCT, he tested negative for SARS-CoV-2 again. Conditioning with fludarabine, cyclophosphamide, and 2-Gy total body irradiation was started and the patient developed lymphopenia. During his hospital stay, he tested positive for SARS-CoV-2 in a PCR test twice but remained asymptomatic. The conditioning regimen was continued as planned. Later during his stay, the patient showed undetectable SARS-CoV-2 load four times. This case documents possible reactivation of SARS-CoV-2 and raises questions about reactivation risks among recipients of stem cell transplants and other immunocompromised patients.

Indexed as

Acute myeloid leukemiaAllogeneic hematopoietic stem cell transplantationCOVID-19SARS-CoV-2

Identifiers

PMID34308258
PMCPMC8294269

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.